Skip to main content

Advertisement

SpringerLink
Log in

Advances in biologic therapy for ulcerative colitis and Crohn’s disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The medical management of inflammatory bowel disease (IBD) has changed considerably since the advent of biologic treatments. In this review we offer a critical evaluation of controlled studies with biologic agents for the management of both Crohn’s disease (CD) and ulcerative colitis (UC). Biologics under evaluation or approved for UC that are discussed include monoclonal antibodies to tumor necrosis factor ([TNF]) infrliximab), inhibitors of adhesion molecules (MLN02 and alicaforsen), anti-CD3 antibodies (visilizumab), and anti-interleukin (IL)-2 receptor antibodies (daclizumab). Biologics under evaluation or approved for CD that are reviewed include three monoclonal antibodies to TNF (infliximab, adalimumab, and certolizumab pegol), monoclonal antibodies against IL-12, interferon-γ, and IL-6 receptors, inhibitors of adhesion molecules (natalizumab, alicaforsen), and growth factors. Only the chimeric monoclonal anti-TNF antibody infliximab is currently available worldwide. The potency of this agent in moderate-to-severe UC and CD has been one of the most important advances in the care of IBD in the past decade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Järnerot G, Hertervig E, Friis-Liby I, et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805–1811.

    Article  PubMed  CAS  Google Scholar 

  2. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462–2476. This pivotal study demonstrated the effect of infliximab in UC. The results were virtually identical to what has been observed in CD, with an identical safety profile and similar rates of mucosal healing.

    Article  PubMed  CAS  Google Scholar 

  3. D’Haens G: Infliximab for ulcerative colitis: finally some answers [editorial]. Gastroenterology 2005, 128:2161–2164.

    Article  PubMed  CAS  Google Scholar 

  4. Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499–2507. Interesting proof-of-concept trial demonstrating a potential target for treating UC; the immunogenicity of this drug may have influenced the results of this trial significantly, as well as its future clinical use.

    Article  PubMed  CAS  Google Scholar 

  5. van DeventerSJH, Tami JA, Wedel MK, et al.: A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004, 53:1646–1651.

    Article  PubMed  CAS  Google Scholar 

  6. Miner PBJ, Wedel MK, Xia S, et al.: Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double blind, active-controlled trial. Aliment Pharmacol Ther 2006, 23:1403–1413.

    Article  PubMed  CAS  Google Scholar 

  7. van DeventerSJ, Wedel MK, Baker BF, et al.: A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006, 23:1415–1425.

    Article  PubMed  CAS  Google Scholar 

  8. Targan S, Salzberg B, Mayer L, et al.: A Phase 1 study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with intravenous steroids. Gastroenterology 2005, 128:A75.

    Article  CAS  Google Scholar 

  9. Van Assche G, Sandborn WJ, Feagan BG, et al.: Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose-ranging trial. Gut 2006, April 7; [Epub ahead of print].

  10. Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088–1094.

    Article  PubMed  CAS  Google Scholar 

  11. Rutgeerts P, Lemmens L, Van Assche G, et al.: Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17:185–192.

    Article  PubMed  CAS  Google Scholar 

  12. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541–1549.

    Article  PubMed  CAS  Google Scholar 

  13. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004, 350:876–885.

    Article  PubMed  CAS  Google Scholar 

  14. Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621–630.

    Article  PubMed  CAS  Google Scholar 

  15. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275–2285.

    Article  PubMed  CAS  Google Scholar 

  16. Van AsscheG, Paintaud G, D’Haens G, et al.: Continuation of immunosuppression is not required to maintain adequate infliximab efficacy in patients with Crohn’s disease bur may improve pharmacokinetics. Gastroenterology 2006, 130:A-142.

    Google Scholar 

  17. Hommes D, Baert F, Van Assche G, et al.: The ideal management of Crohn’s disease: top down versus step up strategies, a randomized controlled trial [abstract 749]. Gastroenterology 2006, 130:A108.

    Google Scholar 

  18. D’Haens G, Hommes D, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn’s disease [abstract 764]. Gastroenterology 2006, 130:A110.

    Google Scholar 

  19. Beaugerie L, Seksik P, Nion-Larmurier I, et al.: Predictors of Crohn’s disease. Gastroenterology 2006, 130:650–656. Elegant retrospective study identifying risk factors for an aggressive disease course. However, the criteria for "aggressive disease" were so loose that the majority of patients fell into the category of "aggressive disease," making the set of criteria of little use for daily clinical practice.

    Article  PubMed  Google Scholar 

  20. Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323–333. Elegant dose-.nding trial demonstrating the short-term effect of adalimumab in active CD. Unfortunately, the trial did not include any endoscopic endpoints. The results of this trial were also not used to optimize later trials with open-label induction schedules.

    Article  PubMed  CAS  Google Scholar 

  21. Colombel JF, Sandborn W, Rutgeerts P, et al.: Adalimumab induces and maintains clinical response and remission in patients with active crohn’s disease: results of the CHARM Trial [late breaking abstract]. Dig Dis Week 2006. Available online at http://www.ddw.org/.

  22. Sandborn WJ, Hanauer S, Loftus EVJ, et al.: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004, 99:1984–1989.

    Article  PubMed  CAS  Google Scholar 

  23. Papadakis KA, Shaye OA, Vasiliauskas EA, et al.: Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75–79.

    Article  PubMed  CAS  Google Scholar 

  24. Schreiber S, Rutgeerts P, Fedorak RN, et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005, 129:807–818. Important study demonstrating the efficacy of certolizumab in active CD. This antibody, unlike infliximab and adalimumab, does not seem to induce apoptosis of inflammatory cells.

    Article  PubMed  CAS  Google Scholar 

  25. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al.: Certolizumab pegol, a humanized anti-TNF pegylated Fab’ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (Precise). Gut 2005, 37:A82.

    Google Scholar 

  26. Sandborn W, Feagan B, Stoinov S, et al.: Certolizuman pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (Precise 1). Gastroenterology 2006, 130:A107.

    Google Scholar 

  27. Mannon PJ, Fuss IJ, Mayer L, et al.: Anti-interleukin-12 antibody for active crohn’s disease. N Engl J Med 2004, 351:2069–2079. This trial shows the efficacy of anti-IL-12 in active CD. The unusual design with different treatment schedules makes future recommendations about how to use this drug optimally somewhat difficult.

    Article  PubMed  CAS  Google Scholar 

  28. Reinisch W, Hommes DW, Van AsscheG, et al.: A doseescalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn’s disease. Gut 2006, 55:1138–1144.

    Article  PubMed  CAS  Google Scholar 

  29. Hommes DW, Mikhajlova TL, Stoinov S, et al.: Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn’s disease. Gut 2006, 55:1131–1137.

    Article  PubMed  CAS  Google Scholar 

  30. Ito H, Takazoe M, Fukuda Y, et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 2004, 126:989–996.

    Article  PubMed  CAS  Google Scholar 

  31. Hommes D, Targan S, Baumgart DC, et al.: A phase I study: visilizumab therapy in Crohn’s disease (CD) patients refractory to infliximab treatment [abstract 769]. Gastroenterology 2006, 130:A111.

    Google Scholar 

  32. Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005, 353:1912–1925. Important and very large trial with the first biologic agent approaching the market outside the anti-TNF agents. Unfortunately, the development was discontinued for toxicity reasons.

    Article  PubMed  CAS  Google Scholar 

  33. Targan SR, Feagan B, Fedorak R, et al.: Natalizumab induces sustained response and remission in patients with active Crohn’s disease: results from the ENCORE trial. Gastroenterology 2006, 130:A108.

    Google Scholar 

  34. Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005, 353:362–368.

    Article  PubMed  Google Scholar 

  35. Langer-Gould A, Atlas SW, Green AJ, et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375–381.

    Article  PubMed  CAS  Google Scholar 

  36. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369–374.

    Article  PubMed  CAS  Google Scholar 

  37. Sandborn WJ, Targan S: A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn’s disease (CD), multiple sclerosis (MS), and rheumatoid arthritis (RA) previously treated with natalizumab in clinical trials [abstract 492]. Gastroenterology 2006, 130:A72.

    Google Scholar 

  38. Yousry TA, et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924–933.

    Article  PubMed  CAS  Google Scholar 

  39. Vespasiani Gentilucci U, Caviglia R, Picardi A, et al.: Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther 2005, 21:1063–1071.

    Article  CAS  Google Scholar 

  40. Slonim AE, Bulone L, Damore MB, et al.: A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med 2000, 342:1633–1637.

    Article  PubMed  CAS  Google Scholar 

  41. Korzenik J, Dieckgraefe B: Immunostimulation in Crohn’s disease: results of a pilot study of G-CSF in mucosal and fistulizing Crohn’s disease. Gastroenterology 2000, 118:A874.

    Article  Google Scholar 

  42. Korzenik J, Pittler A, Dieckgraefe B: Immunostimulation in Crohn’s disease: retreatment and maintenance therapy with GM-CSF. Gastroenterology 2002, 122:A432.

    Google Scholar 

  43. Korzenik JR, Dieckgraefe BK, Valentine JF, et al.: Sargramostim for active Crohn’s disease. N Engl J Med 2005, 352:2193–2201.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Imelda GI Clinical Research Center, Imelda General Hospital, Imeldalaan 9, 2820, Bonheiden, Belgium

    Geert D’Haens MD, PhD

Authors
  1. Geert D’Haens MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Daperno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

D’Haens, G., Daperno, M. Advances in biologic therapy for ulcerative colitis and Crohn’s disease. Curr Gastroenterol Rep 8, 506–512 (2006). https://doi.org/10.1007/s11894-006-0041-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-006-0041-5

Keywords

Search

Navigation